133 related articles for article (PubMed ID: 31734832)
1. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
[TBL] [Abstract][Full Text] [Related]
5. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
Pápai Z; Chen LC; Da Costa D; Blotner S; Vazvaei F; Gleave M; Jones R; Zhi J
Cancer Chemother Pharmacol; 2019 Jul; 84(1):93-103. PubMed ID: 31062077
[TBL] [Abstract][Full Text] [Related]
6. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Blotner S; Chen LC; Ferlini C; Zhi J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
9. Oral idasanutlin in patients with polycythemia vera.
Mascarenhas J; Lu M; Kosiorek H; Virtgaym E; Xia L; Sandy L; Mesa R; Petersen B; Farnoud N; Najfeld V; Rampal R; Dueck A; Hoffman R
Blood; 2019 Aug; 134(6):525-533. PubMed ID: 31167802
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
11. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
[TBL] [Abstract][Full Text] [Related]
12. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
13. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
[TBL] [Abstract][Full Text] [Related]
14. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
16. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.
Patnaik A; Papadopoulos KP; Tolcher AW; Beeram M; Urien S; Schaaf LJ; Tahiri S; Bekaii-Saab T; Lokiec FM; Rezaï K; Buchbinder A
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1499-506. PubMed ID: 23543270
[TBL] [Abstract][Full Text] [Related]
18. Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
So WV; Ou Yang TH; Yang X; Zhi J
Cancer Chemother Pharmacol; 2019 Jan; 83(1):209-213. PubMed ID: 30511219
[TBL] [Abstract][Full Text] [Related]
19. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Faivre SJ; Olszanski AJ; Weigang-Köhler K; Riess H; Cohen RB; Wang X; Myrand SP; Wickremsinhe ER; Horn CL; Ouyang H; Callies S; Benhadji KA; Raymond E
Invest New Drugs; 2015 Dec; 33(6):1206-16. PubMed ID: 26377590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]